DE102004023187A1 - Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie - Google Patents

Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie Download PDF

Info

Publication number
DE102004023187A1
DE102004023187A1 DE102004023187A DE102004023187A DE102004023187A1 DE 102004023187 A1 DE102004023187 A1 DE 102004023187A1 DE 102004023187 A DE102004023187 A DE 102004023187A DE 102004023187 A DE102004023187 A DE 102004023187A DE 102004023187 A1 DE102004023187 A1 DE 102004023187A1
Authority
DE
Germany
Prior art keywords
nucleic acid
tumor
associated antigen
expression
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102004023187A
Other languages
German (de)
English (en)
Inventor
Özlem Dr. Türeci
Sandra Dr. Schneider
Gerd Dr. Helftenbein
Volker Dr. Schlüter
Dirk Dr. Usener
Philippe Dr. Thiel
Ugur Dr. Sahin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ganymed Pharmaceuticals GmbH
Original Assignee
Ganymed Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganymed Pharmaceuticals GmbH filed Critical Ganymed Pharmaceuticals GmbH
Priority to DE102004023187A priority Critical patent/DE102004023187A1/de
Priority to AT05747772T priority patent/ATE468409T1/de
Priority to EP10010167A priority patent/EP2270209A3/de
Priority to DE502005009602T priority patent/DE502005009602D1/de
Priority to EP18157525.9A priority patent/EP3382036A1/de
Priority to EP10010155.9A priority patent/EP2280082B1/de
Priority to EP10010158A priority patent/EP2290103A3/de
Priority to EP10005074A priority patent/EP2239340A3/de
Priority to US11/596,106 priority patent/US7785801B2/en
Priority to JP2007512091A priority patent/JP2007537197A/ja
Priority to ES05747772T priority patent/ES2346067T3/es
Priority to CA002563671A priority patent/CA2563671A1/en
Priority to EP10010168A priority patent/EP2267158A3/de
Priority to EP10010162A priority patent/EP2258868A3/de
Priority to EP10010159A priority patent/EP2275571A3/de
Priority to DK05747772.1T priority patent/DK1759013T3/da
Priority to EP05747772A priority patent/EP1759013B1/de
Priority to CA2820168A priority patent/CA2820168C/en
Priority to PT05747772T priority patent/PT1759013E/pt
Priority to PCT/EP2005/005104 priority patent/WO2005110338A2/de
Priority to EP10010160A priority patent/EP2290104A3/de
Priority to EP10010164A priority patent/EP2287337A3/de
Priority to AU2005244425A priority patent/AU2005244425B2/en
Priority to PL05747772T priority patent/PL1759013T3/pl
Priority to SI200531066T priority patent/SI1759013T1/sl
Priority to EP10010640A priority patent/EP2275572A3/de
Priority to EP10010165A priority patent/EP2267156A3/de
Priority to EP10010166A priority patent/EP2267157A3/de
Priority to EP10010157A priority patent/EP2275570A3/de
Priority to EP10010161A priority patent/EP2258867A3/de
Priority to EP10010156A priority patent/EP2348135A3/de
Priority to EP10010163A priority patent/EP2258869A3/de
Priority to HR20100412T priority patent/HRP20100412T1/hr
Publication of DE102004023187A1 publication Critical patent/DE102004023187A1/de
Priority to US12/851,980 priority patent/US9255131B2/en
Priority to JP2011229287A priority patent/JP5732369B2/ja
Priority to JP2012228762A priority patent/JP5796003B2/ja
Priority to US14/036,969 priority patent/US9533043B2/en
Priority to JP2014240820A priority patent/JP2015083576A/ja
Priority to US15/009,061 priority patent/US20160193335A1/en
Priority to JP2016086914A priority patent/JP6434444B2/ja
Priority to US15/675,148 priority patent/US10724103B2/en
Priority to JP2018042560A priority patent/JP2018104464A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DE102004023187A 2004-05-11 2004-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie Withdrawn DE102004023187A1 (de)

Priority Applications (42)

Application Number Priority Date Filing Date Title
DE102004023187A DE102004023187A1 (de) 2004-05-11 2004-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AU2005244425A AU2005244425B2 (en) 2004-05-11 2005-05-11 Identification of surface-associated antigens for tumor diagnosis and therapy
EP10010164A EP2287337A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE502005009602T DE502005009602D1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
EP18157525.9A EP3382036A1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
EP10010155.9A EP2280082B1 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010158A EP2290103A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10005074A EP2239340A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US11/596,106 US7785801B2 (en) 2004-05-11 2005-05-11 Identification of surface-associated antigens for tumor diagnosis and therapy
JP2007512091A JP2007537197A (ja) 2004-05-11 2005-05-11 腫瘍の診断と治療を目的とした表面会合抗原の同定
ES05747772T ES2346067T3 (es) 2004-05-11 2005-05-11 Identificacion de antigenos asociados a la superficie para el diagnostico y la terapia de tumores.
CA002563671A CA2563671A1 (en) 2004-05-11 2005-05-11 Identification of surface-associated antigens for tumor diagnosis and therapy
EP10010168A EP2267158A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010162A EP2258868A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010159A EP2275571A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DK05747772.1T DK1759013T3 (da) 2004-05-11 2005-05-11 Identificering af overflade-associerede antigener til tumordiagnose
EP05747772A EP1759013B1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
CA2820168A CA2820168C (en) 2004-05-11 2005-05-11 Identification of surface-associated antigens for tumor diagnosis and therapy
PL05747772T PL1759013T3 (pl) 2004-05-11 2005-05-11 Identyfikacja antygenów związanych z powierzchnią w celu rozpoznawania i leczenia nowotworów
PCT/EP2005/005104 WO2005110338A2 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
EP10010160A EP2290104A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
AT05747772T ATE468409T1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie
PT05747772T PT1759013E (pt) 2004-05-11 2005-05-11 Identificação de antigénios associados à superfície para diagnóstico e terapia de tumores
EP10010167A EP2270209A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
SI200531066T SI1759013T1 (sl) 2004-05-11 2005-05-11 Identificiranje s površino povezanih antigenov za tumorsko diagnozo in terapijo
EP10010640A EP2275572A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010165A EP2267156A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010166A EP2267157A3 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten Antigenen für die Tumordiagnose und -Therapie
EP10010157A EP2275570A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010161A EP2258867A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010156A EP2348135A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP10010163A EP2258869A3 (de) 2004-05-11 2005-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
HR20100412T HRP20100412T1 (hr) 2004-05-11 2005-05-11 Identifikacija površinskih antigena radi dijagnoze i liječenja tumora
US12/851,980 US9255131B2 (en) 2004-05-11 2010-08-06 Identification of surface-associated antigens for tumor diagnosis and therapy
JP2011229287A JP5732369B2 (ja) 2004-05-11 2011-10-18 腫瘍の診断と治療を目的とした表面会合抗原の同定
JP2012228762A JP5796003B2 (ja) 2004-05-11 2012-10-16 腫瘍の診断と治療を目的とした表面会合抗原の同定
US14/036,969 US9533043B2 (en) 2004-05-11 2013-09-25 Identification of surface-associated antigens for tumor diagnosis and therapy
JP2014240820A JP2015083576A (ja) 2004-05-11 2014-11-28 腫瘍の診断と治療を目的とした表面会合抗原の同定
US15/009,061 US20160193335A1 (en) 2004-05-11 2016-01-28 Identification of Surface-Associated Antigens for Tumor Diagnosis and Therapy
JP2016086914A JP6434444B2 (ja) 2004-05-11 2016-04-25 腫瘍の診断と治療を目的とした表面会合抗原の同定
US15/675,148 US10724103B2 (en) 2004-05-11 2017-08-11 Identification of surface associated antigen FLJ31461 for tumor diagnosis and therapy
JP2018042560A JP2018104464A (ja) 2004-05-11 2018-03-09 腫瘍の診断と治療を目的とした表面会合抗原の同定

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004023187A DE102004023187A1 (de) 2004-05-11 2004-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Publications (1)

Publication Number Publication Date
DE102004023187A1 true DE102004023187A1 (de) 2005-12-01

Family

ID=35064875

Family Applications (2)

Application Number Title Priority Date Filing Date
DE102004023187A Withdrawn DE102004023187A1 (de) 2004-05-11 2004-05-11 Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE502005009602T Expired - Lifetime DE502005009602D1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE502005009602T Expired - Lifetime DE502005009602D1 (de) 2004-05-11 2005-05-11 Identifizierung von oberflächen-assoziierten antigenen für die tumordiagnose und -therapie

Country Status (14)

Country Link
US (5) US7785801B2 (https=)
EP (18) EP2258867A3 (https=)
JP (6) JP2007537197A (https=)
AT (1) ATE468409T1 (https=)
AU (1) AU2005244425B2 (https=)
CA (2) CA2820168C (https=)
DE (2) DE102004023187A1 (https=)
DK (1) DK1759013T3 (https=)
ES (1) ES2346067T3 (https=)
HR (1) HRP20100412T1 (https=)
PL (1) PL1759013T3 (https=)
PT (1) PT1759013E (https=)
SI (1) SI1759013T1 (https=)
WO (1) WO2005110338A2 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102004023187A1 (de) * 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
US8535677B2 (en) 2006-06-06 2013-09-17 Oxford Biotherapeutics, Ltd. Antibody drug conjugate treatment of colorectal cancer
GB0611116D0 (en) * 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
EP2050466B1 (en) * 2006-08-14 2015-10-28 Chugai Seiyaku Kabushiki Kaisha Diagnosis and treatment of cancer using anti-desmoglein-3 antibodies
DE102007034993A1 (de) * 2007-07-26 2009-01-29 Hanna Diehl Lösliches Cadherin 17 für die Diagnose und Risikostratifizierung von Darmtumor oder Darmkrebs
CA2729133C (en) * 2008-06-25 2014-12-30 Institut Pasteur Korea Genome wide visual identification of human co-factors of hiv-1 infection
WO2010041349A1 (ja) * 2008-10-10 2010-04-15 独立行政法人 放射線医学総合研究所 子宮頚部腺癌の診断又は子宮頸癌の予後の診断のためのマーカー
DK2421898T3 (en) 2009-04-20 2016-05-30 Oxford Biotherapeutics Ltd Cadherin-17 SPECIFIC ANTIBODIES
SG185027A1 (en) * 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
US20130259878A1 (en) * 2010-10-20 2013-10-03 Oxford Biotherapeutics Ltd Antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
PL3892295T3 (pl) 2011-05-24 2023-07-24 BioNTech SE Zindywidualizowane szczepionki przeciwnowotworowe
CN102311242B (zh) * 2011-05-27 2014-10-01 刘长福 一种造纸废液生产的水溶性高分子助磨剂及制造方法
KR101314828B1 (ko) * 2011-09-26 2013-10-04 한국원자력연구원 비소세포성 폐암에서 ｔｍ４ｓｆ４의 발현 또는 활성의 조절을 통한 방사선 저항성 및 암세포의 성장, 전이, 및 침윤능력을 저하시키는 방법
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP3417874B1 (en) 2012-11-28 2024-09-11 BioNTech SE Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
AU2014343379B2 (en) 2013-11-04 2019-02-14 Uti Limited Partnership Methods and compositions for sustained immunotherapy
CN113791220A (zh) 2014-09-10 2021-12-14 豪夫迈·罗氏有限公司 免疫原性突变体肽筛选平台
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP6492914B2 (ja) 2015-04-15 2019-04-03 株式会社デンソー 光走査装置
ES2939013T3 (es) * 2015-04-20 2023-04-18 Consejo Superior Investigacion Agentes que se unen específicamente al motivo RGD de la cadherina 17 humana, la cadherina 5 humana, la cadherina 6 humana y la cadherina 20 humana
EP3291832B1 (en) 2015-05-06 2025-09-03 UTI Limited Partnership Nanoparticle compositions for sustained therapy
US11254744B2 (en) 2015-08-07 2022-02-22 Imaginab, Inc. Antigen binding constructs to target molecules
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
SI3383920T1 (sl) 2015-11-30 2024-06-28 The Regents Of The University Of California Dostava tumorsko specifičnega koristnega tovora in imunska aktivacija z uporabo humanega protitelesa, ki cilja visoko specifičen površinski antigen tumorskih celic
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
US11241455B2 (en) 2016-01-15 2022-02-08 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Methods of treating disease by metabolic control of T-cell differentiation
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
CN106919801B (zh) * 2017-03-08 2023-07-18 杭州大伽信息科技有限公司 一种免疫组织化学染色辅助分析系统及使用方法
WO2018224166A1 (en) 2017-06-09 2018-12-13 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
CA3083748A1 (en) 2017-11-29 2019-06-06 Uti Limited Partnership Methods of treating autoimmune disease
WO2019183683A1 (en) * 2018-03-29 2019-10-03 The University Of Newcastle Diagnostic and prognostic methods for estrogen-induced cancers
WO2020263796A1 (en) * 2019-06-23 2020-12-30 Guangdong Tcrcure Biopharma Technology Co., Ltd. Anti-alpp car-t cell therapy
US12421309B2 (en) 2019-12-06 2025-09-23 Korea Atomic Energy Research Institute Anti-TM4SF4 antibody and uses thereof
CN117597363A (zh) * 2021-06-18 2024-02-23 韩国原子力研究院 抗-tm4sf4人源化抗体及其用途

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4732847A (en) * 1981-06-09 1988-03-22 University Of Hawaii Monoclonal antibodies for DNA-RNA hybrid complexes and their uses
US5081227A (en) * 1988-03-04 1992-01-14 La Jolla Cancer Research Foundation Germ cell alkaline phosphatase
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
AU3178393A (en) 1991-11-27 1993-06-28 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Nucleotide and amino acid sequence of pemphigus vulgaris antigen and methods of use
US5677139A (en) 1995-04-21 1997-10-14 President And Fellows Of Harvard College In vitro differentiation of CD34+ progenitor cells into T lymphocytes
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
JP2003530816A (ja) 1998-09-28 2003-10-21 カイロン コーポレイション ヒト遺伝子および遺伝子発現産物
EP1252300B1 (en) * 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
KR100374423B1 (ko) * 2000-04-25 2003-03-28 주식회사 아이씨엔지 다수의 ｍａｇｅ 아형 또는 ｇａｇｅ 아형을 인식하는암진단용 프라이머
CA2411601A1 (en) * 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
ES2284678T3 (es) * 2000-08-15 2007-11-16 Immunex Corporation Polipeptidos de claudinas.
US6697557B2 (en) * 2000-10-04 2004-02-24 University Of South Florida Two-dimensional optical filter and associated methods
DE10057894A1 (de) * 2000-11-22 2002-06-06 Adnagen Gmbh Diagnose-Kit, DNS-Chip sowie Verfahren zur Diagnostik oder Behandlungskontrolle bei Hodenkrebs
AU2002309583A1 (en) 2001-04-18 2002-11-05 Protein Desing Labs, Inc. Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20050037445A1 (en) * 2001-06-25 2005-02-17 Poulsen Hans Skovgaard Oncology drug innovation
US20040076955A1 (en) * 2001-07-03 2004-04-22 Eos Biotechnology, Inc. Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2003018621A2 (en) * 2001-08-23 2003-03-06 Oxford Biomedica (Uk) Limited Genes
JP2003088388A (ja) * 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1293569A3 (en) * 2001-09-14 2004-03-31 Research Association for Biotechnology Full-length cDNAs
DE10211088A1 (de) 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2522184A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Of New York Desmoglein 4 is a novel gene involved in hair growth
WO2004106511A1 (ja) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
DE102004023187A1 (de) 2004-05-11 2005-12-01 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie

Also Published As

Publication number Publication date
EP2290104A3 (de) 2011-06-22
JP2015083576A (ja) 2015-04-30
EP2348135A3 (de) 2011-10-19
EP2270209A3 (de) 2011-04-20
EP2267158A3 (de) 2011-04-06
EP2290103A3 (de) 2011-06-22
EP2290103A2 (de) 2011-03-02
EP1759013B1 (de) 2010-05-19
JP2012077085A (ja) 2012-04-19
EP2258867A2 (de) 2010-12-08
EP2280082A3 (de) 2011-05-18
EP2239340A2 (de) 2010-10-13
JP5732369B2 (ja) 2015-06-10
CA2563671A1 (en) 2005-11-24
EP2290104A2 (de) 2011-03-02
EP2267156A3 (de) 2011-04-20
PT1759013E (pt) 2010-08-17
AU2005244425B2 (en) 2011-10-13
EP2275570A2 (de) 2011-01-19
US10724103B2 (en) 2020-07-28
US9255131B2 (en) 2016-02-09
EP2275571A2 (de) 2011-01-19
JP2013032381A (ja) 2013-02-14
EP2280082A2 (de) 2011-02-02
JP2016179986A (ja) 2016-10-13
US7785801B2 (en) 2010-08-31
EP1759013A2 (de) 2007-03-07
EP2267158A2 (de) 2010-12-29
JP5796003B2 (ja) 2015-10-21
EP2287337A3 (de) 2011-04-20
EP2258869A3 (de) 2011-04-06
EP2267156A2 (de) 2010-12-29
AU2005244425A1 (en) 2005-11-24
EP2258869A2 (de) 2010-12-08
EP2258867A3 (de) 2011-04-06
EP2275571A3 (de) 2012-11-21
DE502005009602D1 (de) 2010-07-01
EP2270209A2 (de) 2011-01-05
JP2018104464A (ja) 2018-07-05
ES2346067T3 (es) 2010-10-08
EP2287337A2 (de) 2011-02-23
EP2275570A3 (de) 2011-06-22
US20140120085A1 (en) 2014-05-01
US20110014628A1 (en) 2011-01-20
DK1759013T3 (da) 2010-08-30
EP2267157A3 (de) 2011-05-11
CA2820168A1 (en) 2005-11-24
JP2007537197A (ja) 2007-12-20
EP2258868A3 (de) 2011-04-06
SI1759013T1 (sl) 2010-09-30
JP6434444B2 (ja) 2018-12-05
PL1759013T3 (pl) 2010-10-29
CA2820168C (en) 2019-08-20
US9533043B2 (en) 2017-01-03
ATE468409T1 (de) 2010-06-15
WO2005110338A3 (de) 2006-06-29
EP2275572A3 (de) 2011-05-11
EP2267157A2 (de) 2010-12-29
EP2275572A2 (de) 2011-01-19
WO2005110338A2 (de) 2005-11-24
US20160193335A1 (en) 2016-07-07
EP2239340A3 (de) 2010-11-17
US20180169236A1 (en) 2018-06-21
EP2348135A2 (de) 2011-07-27
EP2280082B1 (de) 2016-08-10
US20080193454A1 (en) 2008-08-14
EP2258868A2 (de) 2010-12-08
EP3382036A1 (de) 2018-10-03
HRP20100412T1 (hr) 2010-09-30

Similar Documents

Publication Publication Date Title
EP2280082B1 (de) Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
EP1664113B1 (de) Identifizierung von tumorassoziierten zelloberflächen-antigenen für die diagnose und therapie
EP2327417B1 (de) Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und- therapie

Legal Events

Date Code Title Description
8181 Inventor (new situation)

Inventor name: SCHLUETER, VOLKER, DR., 82061 NEURIED, DE

Inventor name: T?RECI, OZLEM, DR., 55116 MAINZ, DE

Inventor name: HELFTENBEIN, GERD, DR., 35329 GEMUENDEN, DE

Inventor name: THIEL, PHILIPPE, DR., 55268 NIEDER-OLM, DE

Inventor name: USENER, DIRK, DR., 65185 WIESBADEN, DE

Inventor name: SCHNEIDER, SANDRA, DR., 68199 MANNHEIM, DE

Inventor name: SAHIN, UGUR, DR., 55116 MAINZ, DE

8181 Inventor (new situation)

Inventor name: THIEL, PHILIPPE, DR., 82152 PLANEGG, DE

Inventor name: USENER, DIRK, DR., 65193 WIESBADEN, DE

Inventor name: SCHNEIDER, SANDRA, DR., 76297 STUTENSEE, DE

Inventor name: HELFTENBEIN, GERD, DR., 35329 GEMUENDEN, DE

Inventor name: SAHIN, UGUR, DR., 55116 MAINZ, DE

Inventor name: SCHLUETER, VOLKER, DR., 82061 NEURIED, DE

Inventor name: TUERECI, OEZLEM, DR., 55116 MAINZ, DE

R012 Request for examination validly filed

Effective date: 20110428

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee